Research graph
References from Personalized management of platelet transfusion refractoriness: risk factors, cross-matching, and IVIG strategies. Local targets link to admitted publications; unresolved targets remain external evidence.
Platelet transfusions
10.1016/s0140-6736(07)61198-2 · 2007 · External reference
Platelet transfusion refractoriness
10.1111/j.1365-2141.2008.07189.x · 2008 · External reference
The clinical impact of platelet refractoriness: correlation with bleeding and survival
10.1111/j.1537-2995.2008.01799.x · 2008 · External reference
HLA Alloimmunization against platelet transfusions: pathophysiology, significance, prevention and management
10.1111/j.1399-0039.2012.01852.x · 2012 · External reference
Frequency and causes of refractoriness in multiply transfused patients
10.1007/s002770050280 · 1997 · External reference
Prevention of platelet transfusion refractoriness by platelet antigen gene matching: a systematic review and meta-analysis
10.21037/apm-21-2603 · 2021 · External reference
Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients
10.1182/blood-2003-08-2724 · 2005 · External reference
Platelet transfusion: alloimmunization and refractoriness
10.1053/j.seminhematol.2019.10.001 · 2020 · External reference
Managing the platelet refractory patient
10.1111/voxs.12073 · 2014 · External reference
Management of the platelet refractory patient
10.1016/j.hoc.2016.01.008 · 2016 · External reference
Platelet transfusion for patients with cancer: american society of clinical oncology clinical practice guideline update
10.1200/jco.2017.76.1734 · 2018 · External reference
Guidelines for the use of platelet transfusions
10.1111/bjh.14423 · 2017 · External reference
Guidance on platelet transfusion for patients with hypoproliferative thrombocytopenia
10.1016/j.tmrv.2014.11.004 · 2015 · External reference
Incidence of transfusion-induced platelet-reactive antibodies evaluated by specific assays for the detection of human leucocyte antigen and human platelet antigen antibodies
10.1111/j.1423-0410.2007.00958.x · 2007 · External reference
Concurrent intravenous immunoglobulin and platelet transfusion for refractory alloimmune thrombocytopenia in patients undergoing allogeneic hematopoietic stem cell transplantation
10.1016/j.htct.2025.103961 · 2025 · External reference
Treatment of immune-mediated thrombocytopenia purpura with concurrent intravenous immunoglobulin and platelet transfusion: a retrospective review of 40 patients
10.1002/ajh.21060 · 2008 · External reference
Anti-HLA class I alloantibodies in platelet transfusion refractoriness: from mechanisms and determinants to therapeutic prospects
10.3389/fimmu.2023.1125367 · 2023 · External reference
Platelet refractoriness–practical approaches and ongoing dilemmas in patient management
10.1111/bjh.13597 · 2015 · External reference
Platelet transfusion: a clinical practice guideline from the AABB
10.7326/m14-1589 · 2015 · External reference
Guidelines for the use of platelet transfusions
10.1046/j.1365-2141.2003.04468.x · 2003 · External reference
Platelet transfusion refractoriness: how do I diagnose and manage?
10.1182/hematology.2020000137 · 2020 · External reference
The effect of previous pregnancy and transfusion on HLA alloimmunization in blood donors: implications for a transfusion-related acute lung injury risk reduction strategy
10.1111/j.1537-2995.2009.02206.x · 2009 · External reference
Alloimmunization following platelet transfusion: the absence of a dose-response relationship
10.1182/blood.v57.3.395.395 · 1981 · External reference
Antibody response in patients with acute nonlymphocytic leukemia
10.1002/1097-0142(197605)37:5<2177::aid-cncr2820370504>3.0.co;2-d · 1976 · External reference
Managing thrombocytopenia associated with cancer chemotherapy
2015 · External reference
An evaluation of crossmatching, HLA, and ABO matching for platelet transfusions to refractory patients
10.1182/blood.v70.1.23.23 · 1987 · External reference
Evaluation of the effectiveness of platelet crossmatching by the solid-phase red cell adherence assay in adult patients of a tertiary care hospital in Thailand: a retrospective study
10.1002/hsr2.769 · 2022 · External reference
Longitudinal management with crossmatch-compatible platelets for refractory patients: alloimmunization, response to transfusion, and clinical outcomes (CME)
10.1111/j.1537-2995.2012.03593.x · 2012 · External reference
A quasi-experimental study evaluating the efficacy of crossmatch-matched platelet transfusions in hemato-oncology patients with suspected alloimmune platelet refractoriness: a single-centre experience
10.1111/tme.70058 · 2026 · External reference
Intravenous immunoglobulins at the crossroad of autoimmunity and viral infections
10.3390/microorganisms9010121 · 2021 · External reference
A randomized, placebo-controlled trial of intravenous gammaglobulin in alloimmunized thrombocytopenic patients
10.1182/blood.v75.1.313.313 · 1990 · External reference
Antibody response in patients with acute nonlymphocytic leukemia
10.1002/1097-0142(197605)37:5<2177::aid-cncr2820370504>3.0.co;2-d · ExternalCitation · doi-reference
Treatment of immune-mediated thrombocytopenia purpura with concurrent intravenous immunoglobulin and platelet transfusion: a retrospective review of 40 patients
10.1002/ajh.21060 · ExternalCitation · doi-reference
Evaluation of the effectiveness of platelet crossmatching by the solid-phase red cell adherence assay in adult patients of a tertiary care hospital in Thailand: a retrospective study
10.1002/hsr2.769 · ExternalCitation · doi-reference
Frequency and causes of refractoriness in multiply transfused patients
10.1007/s002770050280 · ExternalCitation · doi-reference
Management of the platelet refractory patient
10.1016/j.hoc.2016.01.008 · ExternalCitation · doi-reference
Concurrent intravenous immunoglobulin and platelet transfusion for refractory alloimmune thrombocytopenia in patients undergoing allogeneic hematopoietic stem cell transplantation
10.1016/j.htct.2025.103961 · ExternalCitation · doi-reference
Guidance on platelet transfusion for patients with hypoproliferative thrombocytopenia
10.1016/j.tmrv.2014.11.004 · ExternalCitation · doi-reference
Platelet transfusions
10.1016/s0140-6736(07)61198-2 · ExternalCitation · doi-reference
Guidelines for the use of platelet transfusions
10.1046/j.1365-2141.2003.04468.x · ExternalCitation · doi-reference
Platelet transfusion: alloimmunization and refractoriness
10.1053/j.seminhematol.2019.10.001 · ExternalCitation · doi-reference
Platelet refractoriness–practical approaches and ongoing dilemmas in patient management
10.1111/bjh.13597 · ExternalCitation · doi-reference
Guidelines for the use of platelet transfusions
10.1111/bjh.14423 · ExternalCitation · doi-reference
Platelet transfusion refractoriness
10.1111/j.1365-2141.2008.07189.x · ExternalCitation · doi-reference
HLA Alloimmunization against platelet transfusions: pathophysiology, significance, prevention and management
10.1111/j.1399-0039.2012.01852.x · ExternalCitation · doi-reference
Incidence of transfusion-induced platelet-reactive antibodies evaluated by specific assays for the detection of human leucocyte antigen and human platelet antigen antibodies
10.1111/j.1423-0410.2007.00958.x · ExternalCitation · doi-reference
The clinical impact of platelet refractoriness: correlation with bleeding and survival
10.1111/j.1537-2995.2008.01799.x · ExternalCitation · doi-reference
The effect of previous pregnancy and transfusion on HLA alloimmunization in blood donors: implications for a transfusion-related acute lung injury risk reduction strategy
10.1111/j.1537-2995.2009.02206.x · ExternalCitation · doi-reference
Longitudinal management with crossmatch-compatible platelets for refractory patients: alloimmunization, response to transfusion, and clinical outcomes (CME)
10.1111/j.1537-2995.2012.03593.x · ExternalCitation · doi-reference
A quasi-experimental study evaluating the efficacy of crossmatch-matched platelet transfusions in hemato-oncology patients with suspected alloimmune platelet refractoriness: a single-centre experience
10.1111/tme.70058 · ExternalCitation · doi-reference
Managing the platelet refractory patient
10.1111/voxs.12073 · ExternalCitation · doi-reference
Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients
10.1182/blood-2003-08-2724 · ExternalCitation · doi-reference
Alloimmunization following platelet transfusion: the absence of a dose-response relationship
10.1182/blood.v57.3.395.395 · ExternalCitation · doi-reference
An evaluation of crossmatching, HLA, and ABO matching for platelet transfusions to refractory patients
10.1182/blood.v70.1.23.23 · ExternalCitation · doi-reference
A randomized, placebo-controlled trial of intravenous gammaglobulin in alloimmunized thrombocytopenic patients
10.1182/blood.v75.1.313.313 · ExternalCitation · doi-reference
Platelet transfusion refractoriness: how do I diagnose and manage?
10.1182/hematology.2020000137 · ExternalCitation · doi-reference
Platelet transfusion for patients with cancer: american society of clinical oncology clinical practice guideline update
10.1200/jco.2017.76.1734 · ExternalCitation · doi-reference
Prevention of platelet transfusion refractoriness by platelet antigen gene matching: a systematic review and meta-analysis
10.21037/apm-21-2603 · ExternalCitation · doi-reference
Anti-HLA class I alloantibodies in platelet transfusion refractoriness: from mechanisms and determinants to therapeutic prospects
10.3389/fimmu.2023.1125367 · ExternalCitation · doi-reference
Intravenous immunoglobulins at the crossroad of autoimmunity and viral infections
10.3390/microorganisms9010121 · ExternalCitation · doi-reference
Platelet transfusion: a clinical practice guideline from the AABB
10.7326/m14-1589 · ExternalCitation · doi-reference
